No abstract

No abstract

In this paper a mixture of Type-I censoring and Type-II progressive censoring schemes, called an adaptive Type-II progressive censoring scheme, is introduced for life testing or reliability experiments. For this censoring scheme, the effective sample size m is fixed in advance and the progressive censoring scheme is provided but the number of items progressively removed from the experiment upon failure may change during the experiment.If the experimental time exceeds a prefixed time T but the number of observed failures does not reach m, we terminate the experiment as soon as possible by adjusting the number of items progressively removed from the experiment upon failure. Computational formulae for the expected total test time are provided. Point and interval estimation of the failure rate for exponentially distributed failure times are discussed for this censoring scheme. The various methods are compared using Monte Carlo simulation.

No abstract

No abstract

BackgroundNasopharyngeal carcinoma (NPC) is an epithelial malignancy strongly associated with Epstein-Barr virus (EBV). AT13387 is a novel heat shock protein 90 (Hsp90) inhibitor, which inhibits the chaperone function of Hsp90 and reduces expression of Hsp90-dependent client oncoproteins. This study aimed to evaluate both the in vitro and in vivo antitumor effects of AT13387 in the EBV-positive NPC cell line C666-1.ResultsOur results showed that AT13387 inhibited C666-1 cell growth and induced cellular senescence with the downregulation of multiple Hsp90 client oncoproteins EGFR, AKT, CDK4, and restored the protein expression of negative cell cycle regulator p27. We also studied the ability of AT13387 to restore p27 expression by downregulation of AKT and the p27 ubiquitin mediator, Skp2, using AKT inhibitor and Skp2 siRNA. In the functional study, AT13387 inhibited cell migration with downregulation of a cell migration regulator, HDAC6, and increased the acetylation and stabilization of α-tubulin. We also examined the effect of AT13387 on putative cancer stem cells (CSC) by 3-D tumor sphere formation assay. AT13387 effectively reduced both the number and size of C666-1 tumor spheres with decreased expression of NPC CSC-like markers CD44 and SOX2. In the in vivo study, AT13387 significantly suppressed tumor formation in C666-1 NPC xenografts.ConclusionAT13387 suppressed cell growth, cell migration, tumor sphere formation and induced cellular senescence on EBV-positive NPC cell line C666-1. Also, the antitumor effect of AT13387 was demonstrated in an in vivo model. This study provided experimental evidence for the preclinical value of using AT13387 as an effective antitumor agent in treatment of NPC.

No abstract

No abstract